PD-1 Sponsors Expand Into Bladder, Head & Neck Cancer
Executive Summary
Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.
You may also be interested in...
Bristol Shrugs Off Lirilumab Phase II Mono Trial Failure; Eyes Combo Trials
Bristol says its combination development program for lirilumab - licensed from Innate Pharma in 2011 – remains unaffected by news the anti-KIR checkpoint inhibitor failed in a Phase II trial in elderly patients with acute myeloid leukemia as a maintenance monotherapy.
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
The latest drug development news and highlights from our FDA Performance Tracker.